T4 200 - Pharmaceutical Grade

Levothyroxine sodium, introduced as Synthroid in 1955, was the first synthetic thyroid hormone widely used in the U.S. Its widespread adoption in hypothyroidism treatment led to near-monopoly status. Flint Laboratories controlled the market until generics challenged its dominance in the 1980s. Attempting to defend its product, Flint funded a study, later blocked from publication due to unfavorable results. A legal dispute forced the study's release in 1997, revealing generics' equal efficacy and prompting a $135 million settlement for misleading marketing.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about T4 200 by Pharmaceutical Grade, consult with your doctor or healthcare professional.